UnitedHealth delivered a positive first quarter, with management highlighting advances in pricing discipline, digital adoption, and operational improvements as central to the company’s performance. CEO Stephen Hemsley emphasized that actions taken in the prior year—including leadership refresh and targeted investments—are now producing results across all major business segments. Notably, the company’s focus on embedding value-based care and leveraging digital platforms led to improved patient outcomes and operational efficiency, as nearly half of UnitedHealthcare members now use digital tools for access and services.
Is now the time to buy UNH? Find out in our full research report (it’s free for active Edge members).
UnitedHealth (UNH) Q1 CY2026 Highlights:
- Revenue: $111.7 billion vs analyst estimates of $109.8 billion (2% year-on-year growth, 1.7% beat)
- Adjusted EPS: $7.23 vs analyst estimates of $6.61 (9.4% beat)
- Adjusted EBITDA: $10.06 billion vs analyst estimates of $9.50 billion (9% margin, 5.9% beat)
- Management raised its full-year Adjusted EPS guidance to $18.25 at the midpoint, a 2.8% increase
- Operating Margin: 8%, in line with the same quarter last year
- Market Capitalization: $322.1 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From UnitedHealth’s Q1 Earnings Call
- Albert Rice (UBS) asked about Medicare Advantage cost trends and whether utilization was running above or below the 10% pricing assumption. Chief Executive Officer Stephen Hemsley and UnitedHealthcare CEO Timothy Noel indicated trends remain elevated but in line with expectations, with no inflection point yet observed.
- Kevin Fischbeck (Bank of America) inquired about the impact of patient acuity and provider billing on cost trends across all products. Noel explained that enhanced early intervention tools and targeted network actions are helping manage these trends, particularly in Medicare Advantage, but that overall activity remains high.
- Andrew Mok (Barclays) questioned the drivers behind Optum Health’s outperformance and the reason for profit seasonality. Optum Health President Krista Nelson attributed improvements to focused clinical management and operating execution, while CFO Wayne DeVeydt noted that incentive compensation timing and seasonality are influencing profit distribution.
- Lisa Gill (JPMorgan) sought clarity on the impact of new PBM legislation and potential changes to group purchasing organization (GPO) structures. Chief Pharmacy Officer Jon Mahrt confirmed that UnitedHealth’s GPO is already U.S.-domiciled, and said recent legislative impacts have been factored into guidance, though he expressed concern over access issues in specific states like Tennessee.
- Ann Hynes (Mizuho Securities) asked for targets on AI-driven cost savings and the potential for AI to structurally shift Optum Insight’s growth. Chief Digital Officer Sandeep Dadlani said internal AI returns are targeted at 2:1, with many programs expected to pay back within 12 to 18 months, but management is not yet providing formal guidance on the compounding effect.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will closely monitor (1) the pace of AI adoption and resulting operational efficiencies, (2) progress on margin recovery in Medicare and commercial insurance lines through pricing and contract renegotiations, and (3) the rollout and impact of value-based care initiatives within Optum Health. Additionally, we will track regulatory developments around Medicare risk adjustment and PBM legislation, which could influence both revenue streams and cost structures.
UnitedHealth currently trades at $353.62, up from $323.48 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
